ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells
dc.contributor.author | Chittasupho, Chuda | |
dc.contributor.author | Manikwar, Prakash | |
dc.contributor.author | Krise, Jeffrey P. | |
dc.contributor.author | Siahaan, Teruna J. | |
dc.contributor.author | Berkland, Cory J. | |
dc.date.accessioned | 2017-05-08T18:41:55Z | |
dc.date.available | 2017-05-08T18:41:55Z | |
dc.date.issued | 2010-02-01 | |
dc.identifier.citation | Chittasupho, C., Manikwar, P., Krise, J. P., Siahaan, T. J., & Berkland, C. (2010). cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Molecular Pharmaceutics, 7(1), 146. http://doi.org/10.1021/mp900185u | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/24022 | |
dc.description.abstract | Leukocyte function associated antigen-1 (LFA-1) is a primary cell adhesion molecule of leukocytes required for mediating cellular transmigration into sites of inflammation via the vascular endothelium. A cyclic peptide, cIBR, possesses high affinity for LFA-1 and conjugation to the surface of poly(dl-lactic-co-glycolic acid) nanoparticles can specifically target and deliver the encapsulated agents to T cells expressing LFA-1. The kinetics of targeted nanoparticle uptake by acute lymphoblastic leukemia T cells was investigated by flow cytometry and microscopy and compared to untargeted nanoparticles. The specificity of targeted nanoparticles binding to the LFA-1 integrin was demonstrated by competitive inhibition using free cIBR peptide or using the I domain of LFA-1 to inhibit the binding of targeted nanoparticles. The uptake of targeted nanoparticles was concentration and energy dependent. The cIBR-conjugated nanoparticles did not appear to localize with lysosomes whereas untargeted nanoparticles were detected in lysosomes in 6 hrs and steadily accumulated in lysosomes for 24 hrs. Finally, T-cell adhesion to epithelial cells was inhibited by cIBR-nanoparticles. Thus, nanoparticles displaying the cIBR ligand may offer a useful targeted drug delivery system as an alternative treatment of inflammatory diseases involving transmigration of leukocytes. | en_US |
dc.publisher | American Chemical Society | en_US |
dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://doi.org/10.1021/mp900185u. | en_US |
dc.subject | LFA-1 | en_US |
dc.subject | Leukocytes | en_US |
dc.subject | Peptide | en_US |
dc.subject | Nanoparticles | en_US |
dc.subject | Targeting | en_US |
dc.title | cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Chittasupho, Chuda | |
kusw.kuauthor | Manikwar, Prakash | |
kusw.kuauthor | Krise, Jeffrey P. | |
kusw.kuauthor | Siahaan, Teruna J. | |
kusw.kuauthor | Berkland, Cory J. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1021/mp900185u | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC2815130 | en_US |
dc.rights.accessrights | openAccess |